APRIL 8, 2024

Press Releases

Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone) Promising preclinical results obtained in obesity support the OBA Phase 2 clinical study expected to start mid-2024 Biophytis announces that it is launching a new clinical development program named OBA, with BIO101 (20- hydroxyecdysone) as a potential treatment for obesity in combination with…

APRIL 8, 2024

Press Releases, Press Releases

Biophytis announces its 2023 financial results and provides an update on its business activities Biophytis publishes its financial results for the year ended December 31, 2023, and provides an update on the progress of its various programmes. “In 2023, despite a particularly difficult financial environment for the biotech sector, we succeeded in pursuing the development…